



# Occurrence and Genomic Characterization of Clone ST1193 Clonotype 14-64 in Uncomplicated Urinary Tract Infections Caused by *Escherichia coli* in Spain

Isidro García-Meniño,<sup>a,b,c</sup> Pilar Lumbreras,<sup>d,e</sup> Luz Lestón,<sup>a,b</sup> Mónica Álvarez-Álvarez,<sup>d</sup> Vanesa García,<sup>a,b</sup>  Jens Andre Hammerl,<sup>c</sup>  Javier Fernández,<sup>d,e,f,g</sup>  Azucena Mora<sup>a,b</sup>

<sup>a</sup>Laboratorio de Referencia de *Escherichia coli* (LREC), Dpto. de Microbiología e Parasitología, Universidade de Santiago de Compostela (USC), Lugo, Spain

<sup>b</sup>Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago, Spain

<sup>c</sup>Department for Biological Safety, German Federal Institute for Risk Assessment, Berlin, Germany

<sup>d</sup>Servicio de Microbiología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain

<sup>e</sup>Grupo de Microbiología Traslacional, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain

<sup>f</sup>Research & Innovation, Artificial Intelligence and Statistical Department, Pragmatech AI Solutions

<sup>g</sup>CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

Javier Fernández and Azucena Mora contributed equally to this work. Author order was determined based on seniority.

**ABSTRACT** We conducted a prospective, multicenter, specific pilot study on uncomplicated urinary tract infections (uUTI). One-hundred non-duplicated uropathogenic *Escherichia coli* (UPEC) from uUTI occurred in 2020 in women attending 15 primary care centers of a single health region of northern Spain were characterized using a clonal diagnosis approach. Among the high genetic diversity showed by 59 different phylogroup-clonotype combinations, 11 clones accounted for 46% of the isolates: B2-ST73 (CH24-30); B2-ST73 (CH24-103); B2-ST131 (CH40-30); B2-ST141 (CH52-5); B2-ST372 (CH103-9); B2-ST404 (CH14-27); B2-ST404 (CH14-807); B2-ST1193 (CH14-64); D-ST69 (CH35-27); D-ST349 (CH36-54), and F-ST59 (CH32-41). The screening of the UPEC status found that 69% of isolates carried  $\geq 3$  of *chuA*, *fyuA*, *vat*, and *yfcV* genes. Multidrug resistance to at least one antibiotic of  $\geq 3$  antimicrobial categories were exhibited by 30% of the isolates, with the highest rates of resistance against ampicillin/amoxicillin (48%), trimethoprim (35%), norfloxacin (28%), amoxicillin-clavulanic acid (26%), and trimethoprim-sulfamethoxazole (24%). None extended-spectrum beta-lactamase/carbapenemase producer was recovered. According to our results, fosfomycin and nitrofurantoin should be considered as empirical treatment of choice for uUTI by *E. coli* (resistance rates 4% and 2%, respectively). We uncover the high prevalence of the pandemic fluoroquinolone-resistant ST1193 clone (6%) in uUTI, which represents the first report in Spain in this pathology. The genomic analysis showed similar key traits than those ST1193 clones disseminated worldwide. Through the SNP comparison based on the core genome, the Spanish ST1193 clustered with isolates retrieved from the Enterobase, showing high genomic similarity than the global ST1193 described in the United States, Canada and Australia.

**IMPORTANCE** Analyzing the clonal structure and antimicrobial resistance of *E. coli* isolates implicated in uncomplicated urinary tract infections, one of the most frequent visits managed in primary health care, is of interest for clinicians to detect changes in the dynamics of emerging uropathogenic clones associated with the spread of fluoroquinolone resistance. It can also provide consensus concerning optimal control and antibiotic prescribing.

**KEYWORDS** uncomplicated UTI (uUTI), antimicrobial resistance (AMR), UPEC, ST1193, ST131, fluoroquinolone resistance (FQR), *Escherichia coli*

**Editor** Sadjia Bekal, Institut National de Santé Publique du Québec

**Copyright** © 2022 García-Meniño et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Azucena Mora, [azucena.mora@usc.es](mailto:azucena.mora@usc.es).

The authors declare no conflict of interest.

[This article was published on 23 May 2022 with an error in the Discussion section. The Discussion section text has been updated in the current version, posted on 26 May 2022.]

**Received** 6 January 2022

**Accepted** 26 April 2022

**Published** 23 May 2022

Urinary tract infections (UTIs) are one of the most common diseases in both community and hospital settings. In the United States, UTIs were estimated in approximately 400,000 hospitalizations and \$2.8 billion of costs in 2011 (1). In France, it was estimated in a mean of 70 € for one episode of a suspected UTI and 58 million from the societal perspective (2). In particular, uncomplicated urinary tract infections (uUTIs) are within the most frequent visits managed in primary health care, which implies a high impact on antibiotic prescription in ambulatory medicine (15% to 20%) (3–6). uUTI are referred as episodes of acute cystitis occurring in healthy, premenopausal, and nonpregnant women with no known structural or functional urological abnormalities of the genitourinary tract. The most frequent symptoms associated with uUTIs are strong and persistent urge to urinate, pelvic pain, burning sensation when urinating, and sign of blood in the urine (7). In Spain, a prospective study at two primary care practices in 2007 found that infectious diseases accounted for one third of the visits to a general practitioner. Among 4,353 infections observed in patients with a mean age of 44.1 years, UTIs were the third cause (452; 10.4%), after respiratory (2,196; 50.4%) and skin infections (586, 13.5%) (8).

*Escherichia coli* is the most commonly etiological agent reported in UTIs (75% to 95%) (9). Unfortunately, there is a dramatic increase of multidrug resistance (MDR) within uropathogenic *E. coli* (UPEC), mainly due to a few globally disseminated clones such as ST131-*H30R* or ST1193-*H64*, which further compromises treatment (7, 10–16). While isolates causing complicated UTI have been widely analyzed and reported (17–19), studies on uUTIs are still lacking because urine culture is rarely included in the routine diagnosis. In fact, at clinical level, the European Association of Urology and the Infectious Diseases Society of America (IDSA) recommends the treatment for uUTIs based on an empirical antimicrobial therapy guided by local susceptibility patterns without urine culture (20). Therefore, microbiological urine testing prior to treatment is only essential for patients with complicated UTIs (structural or functional abnormalities in genitourinary tracts), or when empirical therapy fails (10). In consequence, microbiological data lack for up to 70% of females with UTI symptoms. Based on a four-country primary care cohort study, Butler et al. (21) concluded that variation in management of uUTI at a country primary care network level is clinically unwarranted and highlights a lack of consensus concerning optimal symptom control and antibiotic prescribing.

Based on what was stated above, we aimed the characterization of the predominant uropathogenic *E. coli* (UPEC) lineages associated with uUTIs to assess the importance of implementing specific surveillance programs to treat these infections.

## RESULTS

**Virulence status.** The screening of virulence traits associated with a higher efficiency in the colonization of the urinary tract revealed that 69 of the 100 uUTI isolates conformed the UPEC status ( $\geq 3$  of specific virulence traits *chuA*, *fyuA*, *vat*, and *yfcV*). Individually, *chuA*, *fyuA*, *vat*, and *yfcV* were present in 91%, 91%, 59%, and 67% of the isolates, respectively. Besides, the screening of *iutA* and *kpsMIII* as prevailing genes within extraintestinal infections showed that 44% of the *E. coli* were carriers of both. Individually, they were detected in 55% and 80% of the isolates, respectively (Table S1).

**uUTI clonal groups.** The eight *E. coli* phylogroups *sensu stricto* (A, B1, B2, C, D, E, F, and G) were represented among the 100 uUTI isolates. However, B2 and D were the most prevalent, accounting for 67% and 14% of the isolates, respectively. The remaining 19 uUTI *E. coli* belonged to A (5%), B1 (5%), E (3%), F (3%), C (2%), and G (1%). The predictor genes associated with a higher efficiency in the colonization of the urinary tract, and therefore positive for the UPEC status was found within the isolates belonging to phylogroups B2 (65 of 67 isolates), F (3), and G (1). Both *iutA* and *kpsMIII* virulence traits were present in 44 isolates of phylogroups A (2 out of 5 isolates), B2 (32 of 67), D (7 of 14), and F (3) (Table S1).

By clonotyping, 59 different phylogroup-clonotype (PG-CH) combinations were revealed, and those represented by  $\geq 3$  isolates were further investigated by multilocus sequence typing (MLST). As a result, 46% of the 100 uUTI isolates belonged to one

**TABLE 1** Prevalent clones ( $\geq 3$  isolates) within the 100 uUTI *E. coli*, virulence traits, MDR, and FQR

Phylogroup-ST	Clonotype (CH)	No. isolates (N = 46)	UPEC status (N = 36)	<i>iutA</i> + <i>kpsMII</i> (N = 26)	MDR (N = 16)	FQR (N = 10)
B2-ST141	CH52-5	6	6	0	0	0
B2-ST1193	CH14-64	6	6	6	4	6
B2-ST73	CH24-103	5	5	0	1	0
	CH24-30	3	3	3	2	0
B2-ST372	CH103-9	4	4	0	2	1
B2-ST404	CH14-27	4	4	4	0	0
	CH14-807	3	2	2	0	0
B2-ST131 <sup>a</sup>	CH40-30	3	3	3	3	0
D-ST69	CH35-27	5	0	3	1	0
D-ST349	CH36-54	4	0	2	3	2
F-ST59	CH32-41	3	3	3	0	1

<sup>a</sup>Isolates belonging to the clonal group ST131 appeared associated to three clonotypes: CH40-30, CH40-22, CH40-1196 (with three, one, and one isolates, respectively). While only the three isolates of clone B2-ST131 (CH40-30) exhibited MDR, B2-ST131 (CH40-1193) showed FQR.

of the following 11 clones: B2-ST141 (CH52-5), six isolates; B2-ST1193 (CH14-64), six isolates; B2-ST73 (CH24-103), six isolates; B2-ST73 (CH24-30), three isolates; B2-ST372 (CH103-9), four isolates; B2-ST404 (CH14-27), four isolates; B2-ST404 (CH14-807), three isolates; B2-ST131 (CH40-30), three isolates; D-ST69 (CH35-27), five isolates; D-ST349 (CH36-54), four isolates; and F-ST59 (CH32-41), three isolates. Most isolates (36 of 46) belonging to nine of the 11 prevalent clones were carriers of  $\geq 3$  of specific traits *chuA*, *fyuA*, *vat*, and *yfcV* associated with higher virulence, and therefore, positive for the UPEC status; and only clones D-ST349 (CH-54) and D-ST69 (CH35-27) were characteristically negative. Regarding the presence or absence of both *iutA* and *kpsMII*, we observed a positive correlation with isolates belonging to clones B2-ST73 (CH24-30), B2-ST131 (CH40-30), B2-ST404 (CH14-27), B2-ST1193 (CH14-64), and F-ST59 (CH32-41). In addition to clonotype CH40-30, determined in three isolates, the pandemic ST131 clonal group appeared also associated to CH40-22 and CH40-1196 (one isolate each) (Table 1; Table S1).

**Antimicrobial susceptibility testing.** Antimicrobial susceptibility testing (AST) showed the highest rates of resistance to ampicillin/amoxicillin (48%), ticarcillin (45%), piperacillin (41%), trimethoprim (35%), norfloxacin (28%), amoxicillin-clavulanic acid (26%), and trimethoprim-sulfamethoxazol (24%). Furthermore, 30% of the uUTI isolates were MDR, being *in vitro* resistant to at least one antibiotic of  $\geq 3$  antimicrobial categories (Table 2). It is important to note that none of the 100 uUTI isolates exhibited phenotypic expression of ESBL enzymes. Regarding colistin, two isolates were categorized as resistant by the MicroScan System but as susceptible by the standard BMD method (both isolates displayed MICs of 0.125 mg/L).

The group of uUTI isolates positive for the UPEC status exhibited lower rates of MDR (18 of 69, 26%) but without significant differences in comparison to those negative for the UPEC status (13 of 31, 42%) ( $P = 0.16$ ). Particularly among the 11 prevalent uUTI clones, the global rate of MDR was 34.8% (16 out of 46 isolates): namely, B2-ST131 (CH40-30) (three isolates), B2-ST1193 (CH14-64) (four of six isolates), D-ST349 (CH36-54) (three of four isolates), B2-ST73 (CH24-30) (two of three isolates), B2-ST372 (CH103-9) (two of four isolates), B2-ST73 (CH24-103) (one of five isolates), and D-ST69 (CH35-27) (one of five isolates) (Table 1).

Fluoroquinolone-resistance (FQR) was exhibited by 28% of the 100 uUTI isolates belonging to 20 different PG-CH combinations, including the six isolates of clone B2-ST1193 (CH14-64), which were further analyzed by whole genome sequencing (WGS) due to the global emergence of this FQR and virulent lineage (Table 1; Table S1).

***In silico* characterization of B2-ST1193 (CH14-64) isolates.** Table 3 summarizes the main traits of the *in silico* characterization. All B2-ST1193 (CH14-64) isolates were subjected to WGS. However, one isolate that had less than 20 times coverage was excluded. SerotypeFinder predicted O75:H5 for all genomes but one (LREC-270), for

**TABLE 2** Rates of antimicrobial resistance interpreted according to EUCAST 2021 breakpoints

Antimicrobial categories	Antimicrobial agent	% Resistant isolates N = 100
Penicillins	Ampicillin/amoxicillin	48
	Piperacillin	41
	Ticarcillin	45
Antipseudomonal penicillins + beta-lactamase inhibitors	Piperacillin-tazobactam	5
Penicillins + beta-lactamase inhibitors	Amoxicillin/clavulanic acid	26
Non-broad spectrum cephalosporins: 1st & 2nd generation	Cefuroxime	3
Broad-spectrum cephalosporins: 3rd & 4th generation	Cefixime	1
	Cefotaxime	0
	Ceftazidime	0
	Cefepime	0
Broad-spectrum cephalosporins + beta-lactamase inhibitor	Ceftolozane-tazobactam	0
	Ceftazidime-avibactam	0
Carbapenems	Imipenem	0
	Ertapenem	0
	Meropenem	0
Monobactams	Aztreonam	1
Fluoroquinolones	Norfloxacin	28
	Ciprofloxacin	18
	Levofloxacin	17
Aminoglycosides	Gentamicin	17
	Tobramycin	16
	Amikacin	4
Glycylcyclines	Tigecycline	0
Nitrofurantoin derivatives	Nitrofurantoin	2
Phosphonic acids	Fosfomicin	4
Folate pathway inhibitors	Trimethoprim	35
	Trimethoprim-sulfamethoxazole	24
Polymyxins	Colistin	0
MDR (resistant to $\geq$ one agent in $\geq$ 3 antimicrobial categories)		30

which O antigen was not typeable (NT:H5). Besides, MLST (seven genes) and CHTyper tools confirmed ST1193 (CH14-64) for all genomes. The alternative MLST scheme based on the eight genes *dinB*, *icdA*, *pabB*, *polB*, *putP*, *trpA*, *trpB*, and *uidA* (22) predicted ST53 (1-7-1-9-20-20-1-6) for all genomes but LREC-270 (ST53-like; *trpA*, 92% identity with allele 20). cgMLSTFinder also differentiated LREC-270, which was assigned as cgST7142, while LREC-265, 269, 273, and 275 were predicted as cgST4085.

All ST1193 genomes presented the same set of chromosomal mutations conferring FQR (*gyrA* S83L, *gyrA* D87N, *parC* S80I, and *parE* L416F), which correlated with the *in vitro* expression. Additionally, other acquired resistance traits were predicted using CGE and CARD databases (Table 3, Table S2). Using VirulenceFinder and VFDB, all genomes but LREC-270 showed the same profile, including a wide number of extraintestinal virulence genes (Table 3, Table S3). Likewise, MobileElementFinder determined the same profile of mobile genetic elements in correlation with AMR and virulence traits except for LREC-270. The plasmidome analysis revealed the presence of an IncF [F-A1:B10] plasmid type in four of five genomes (all but LREC-270), together with small non-conjugative Col-like plasmids in four of them (Table 3). The five ST1193 genomes were predicted as human pathogen (probability > 92%) when analyzed with PathogenFinder. Finally, CRISPRCasFinder found the same types/subtypes of CRISPR-Cas system I within LREC-269, 270, and 275 (Table 3).

Enterobase (<https://enterobase.warwick.ac.uk/>) was searched as a source of genomes belonging to ST1193 (according to the Achtman 7-gene MLST scheme), predicted as cgST4085 and cgST72142, whose assemblies were retrieved for comparative

**TABLE 3** *In silico* characterization and phenotypic AMR of the uUTI ST1193 isolates

ID code <sup>a</sup>	O:H antigens <sup>b</sup>	ST#1/ ST#2 <sup>c</sup>	cgST <sup>d</sup>	CHType <sup>e</sup>	Acquired resistances and point mutations (in bold) <sup>f</sup>	Plasmid content Inc. group [pMLST] <sup>g</sup>	Virulence genes <sup>h</sup>	Mobile genetic elements (& relation to AMR traits) <sup>i</sup>	CRISPR-Cas system / Cas-type/subtype <sup>j</sup>	Phenotypic AMR <sup>k</sup>
51107635 LREC-265	O75:H5	1193/ 53	4085	14-64	<i>b</i> <sub>14-EM-1B'</sub> : <i>aph</i> (3')-Ib, <i>aph</i> (6)-Id; <i>mdf</i> (A), <i>sul</i> 2; <i>sit</i> ABCD <b><i>gyrA</i> S83L, <i>gyrA</i> D87N, <i>parC</i> S80I, <i>parE</i> L416F</b>	IncF [F:-A1:B10] Inc11-I [ST Unknown] IncQ1* ColBS512-like	<i>chuA</i> , <i>fyuA</i> , <i>gad</i> , <i>iha</i> , <i>irp2</i> , <i>iucC</i> , <i>iutA</i> , <i>kpsE</i> , <i>kpsMII_K1</i> , <i>neuC</i> , <i>ompT</i> , <i>papA_F43</i> , <i>sat</i> , <i>senB</i> , <i>sitA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i>	ISEc42 ( <i>mdf</i> (A), <i>ompT</i> ); MITEEc1 ( <i>mdf</i> (A), <i>ompT</i> ); IS30 ( <i>sit</i> ABC, <i>sitA</i> ); ISEc31 ( <i>iha</i> ); IS629 ( <i>papA_F43</i> ); MITEEc1 ( <i>fyuA</i> , <i>irp2</i> , <i>yfcV</i> ); MITEEc1 ( <i>terC</i> )	-	AMP-AM; PIP; TIC; AMC; CIP; LEV; NOR
51140663 LREC-269	O75:H5	1193/ 53	4085	14-64	<i>b</i> <sub>14-EM-1B'</sub> : <i>aph</i> (3')-Ib, <i>aph</i> (6)-Id; <i>mdf</i> (A), <i>mph</i> (A), <i>sul</i> 2, <i>dfra</i> 17; <i>sit</i> ABCD <b><i>gyrA</i> S83L, <i>gyrA</i> D87N, <i>parC</i> S80I, <i>parE</i> L416F</b>	IncF [F:-A1:B10] IncQ1* ColBS512-like ColRNAH-like*	<i>chuA</i> , <i>fyuA</i> , <i>gad</i> , <i>iha</i> , <i>irp2</i> , <i>iucC</i> , <i>iutA</i> , <i>kpsE</i> , <i>kpsMII_K1</i> , <i>neuC</i> , <i>ompT</i> , <i>papA_F43</i> , <i>sat</i> , <i>senB</i> , <i>sitA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i>	ISEc42 ( <i>mdf</i> (A)); MITEEc1 ( <i>mdf</i> (A)); MITEEc1 ( <i>terC</i> ); IS30 ( <i>sit</i> ABCD, <i>sitA</i> ); MITEEc1 ( <i>irp2</i> , <i>yfcV</i> , <i>fyuA</i> ); ISEc31 ( <i>iha</i> ); IS629 ( <i>papA_F43</i> ); IS100 ( <i>iucC</i> , <i>sat</i> , <i>iutA</i> )	Class I / CAS-Type I/Cas3-0-I; CAS-Type IIIA/Csm2-1-IIIA	AMP-AM; PIP; TIC; AMC; CIP; LEV; NOR; TMP; TMP-SMX
51144630 LREC-270	NT:H5	1193/ 53-like	72142	14-64	<i>mdf</i> (A); <i>sit</i> ABCD <b><i>gyrA</i> S83L, <i>gyrA</i> D87N, <i>parC</i> S80I, <i>parE</i> L416F</b>	Inc11-I [ST Unknown] ColBS512-like ColMG828-like	<i>cia</i> , <i>fyuA</i> , <i>gad</i> , <i>iha</i> , <i>irp2</i> , <i>iucC</i> , <i>iutA</i> , <i>kpsE</i> , <i>kpsMII_K1</i> , <i>senB</i> , <i>terC</i> , <i>usp</i>	ISEc31 ( <i>iha</i> )	Class I / CAS-Type I/Cas3-0-I; CAS-Type IIIA/Csm2-1-IIIA	CIP; LEV; NOR
51150996 LREC-273	O75:H5	1193/ 53	4085	14-64	<i>mdf</i> (A); <i>sit</i> ABCD <b><i>gyrA</i> S83L, <i>gyrA</i> D87N, <i>parC</i> S80I, <i>parE</i> L416F</b>	IncF [F:-A1:B10] ColBS512-like ColMG828-like* Col156-like	<i>chuA</i> , <i>fyuA</i> , <i>gad</i> , <i>iha</i> , <i>irp2</i> , <i>iucC</i> , <i>iutA</i> , <i>kpsE</i> , <i>kpsMII_K1</i> , <i>neuC</i> , <i>ompT</i> , <i>papA_F43</i> , <i>sat</i> , <i>senB</i> , <i>sitA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i>	ISEc42 ( <i>mdf</i> (A)); MITEEc1 ( <i>mdf</i> (A)); MITEEc1 ( <i>terC</i> ); IS30 ( <i>sit</i> ABCD, <i>sitA</i> ); ISEc31 ( <i>iha</i> ); IS629 ( <i>papA_F43</i> , <i>iutA</i> , <i>sat</i> , <i>iucC</i> )	-	CIP; LEV; NOR

(Continued on next page)

TABLE 3 (Continued)

ID code <sup>a</sup>	O:H antigens <sup>b</sup>	ST#1/ ST#2 <sup>c</sup>	cgST <sup>d</sup>	CHType <sup>e</sup>	Acquired resistances and point mutations (in bold) <sup>f</sup>	Plasmid content Inc. group [pMLS T] <sup>g</sup>	Virulence genes <sup>h</sup>	Mobile genetic elements (& relation to AMR and virulence traits) <sup>j</sup>	CRISPR-Cas system / Cas-type/subtype <sup>i</sup>	Phenotypic AMR <sup>k</sup>
51152710 LREC-275	O75:H5	1193/ 53	4085	14-64	<b>bla<sub>TEM-1β</sub></b> , <b>aph(3'')-Ib</b> , <b>aph(6)-Id</b> , <b>mdf(A)</b> , <b>su12</b> , <b>dfra14</b> ; <b>sitABCD</b> <b>gyrA S83L</b> , <b>gyrA D87N</b> , <b>parC S80I</b> , <b>parE L416F</b>	IncF [F--A1:B10] IncQ1	<i>chuA</i> , <i>fyuA</i> , <i>gad</i> , <i>iha</i> , <i>irp2</i> , <i>iucC</i> , <i>iutA</i> , <i>kpsE</i> , <i>kpsMII_K1</i> , <i>neuC</i> , <i>ompT</i> , <i>papA_F43</i> , <i>sat</i> , <i>senB</i> , <i>sitA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i>	ISEc42 ( <i>mdf(A)</i> ); MITEEc1 ( <i>mdf(A)</i> ); MITEEc1 ( <i>terC</i> ); MITEEc1 ( <i>irp2</i> ; <i>fyuA</i> ); IS30 ( <i>sitABCD</i> , <i>sitA</i> ); ISEc31 ( <i>iha</i> ); IS629 ( <i>papA_F43</i> , <i>iutA</i> , <i>sat</i> , <i>iucC</i> )	Class I / CAS-Type I/Cas3-0-I; CAS-Type IIIA/Csm2-1-IIIA	AMP-AM; PIP; TIC; CIP; LEV; NOR; TMP; TMP-SMX; FOS

<sup>a</sup>Isolate and genome (LREC) identification.

<sup>b</sup>O and H antigen prediction with SerotypeFinder 2.0;

<sup>c</sup>Sequence types (ST#1 and ST#2) based on two different MLST schemes were applied: *E. coli* #1 (67) and *E. coli* #2 (22), respectively, and retrieved with MLST 2.0.4.

<sup>d</sup>Core genome ST obtained with cgMLSTFinder1.1, software run against the Enterobase database.

<sup>e</sup>Clonotypes;

<sup>f</sup>Acquired antimicrobial resistance genes and/or chromosomal mutations. Resistome: acquired resistance genes: **beta-lactam**, **bla<sub>TEM-1β</sub>**; **aminoglycosides**, **aph(3'')-Ib**, **aph(6)-Id**; **macrolides**, **mdf(A)**, **mph(A)**; **sulphonamides**, **su12**; **trimethoprim**, **dfra14**, **dfra17**; **peroxide**, **sitABCD** (mediates transport of iron and manganese and resistance to hydrogen peroxide). Point mutations: **quinolones** and **fluoroquinolones**, **gyrA S83L**, **TCG-TTG**; **gyrA D87N**, **GAC-AAC**; **parC S80I**, **AGC-ATC**; **parE L416F**, **CTT-TTT**.

<sup>g</sup>replicon/plasmid sequence types, Plasmidome: \*coverage <100%.

<sup>h</sup>Virulence genes, and Virulence determinants: *chuA*, outer membrane hemin receptor; *cia*, colicin Ia; *fyuA*, siderophore receptor; *gad*, glutamate decarboxylase; *iha*, adherence protein; *irp2*, high molecular weight protein 2 non-ribosomal peptide synthetase; *iucC*, aerobactin synthetase; *iutA*, ferric aerobactin receptor; *kpsE*, capsule polysaccharide export inner-membrane protein; *kpsMII\_K1*, polysialic acid transport protein group 2 capsule; *neuC*, polysialic acid capsule biosynthesis protein; *ompT*, outer membrane protease (protein protease 7); *papA\_F43*, major pilin subunit F43; *sat*, secreted autotransporter toxin; *senB*, plasmid-encoded enterotoxin; *sitA*, iron transport protein; *terC*, tellurium ion resistance protein; *usp*, uropathogenic specific protein; *vat*, vacuolating autotransporter toxin; *yfcV*, fimbrial protein.

<sup>i</sup>the mobile genetic elements associated with AMR and virulence traits were also predicted using: CHyper 1.0, ResFinder 4.1, PlasmidFinder 2.1, pMLST 2.0, VirulenceFinder 2.0 and MobileElementFinder 1.03 online tools at the Center of Genomic Epidemiology (<http://www.genomicepidemiology.org/services/>), respectively.

<sup>j</sup>CRISPRCasFinder software (<https://crisprcas.izbc.paris-saclay.fr/>) was used to identify and type CRISPR and Cas systems within the genomes.

<sup>k</sup>Phenotypic resistances were interpreted according to EUCAST 2021 breakpoints. Antimicrobial abbreviation: PIP, piperacillin; TIC, ticarcillin; AMC, amoxicillin-clavulanic acid; AMP-AM, ampicillin-azoxycillin; CIP, ciprofloxacin; LEV, levofloxacin; NOR, norfloxacin; TMP, trimethoprim; TMP-SMX, trimethoprim-sulfamethoxazole; FOS, fosfomycin.

purposes. We found one cgST4085 genome (assembly code ESC\_FA9684AA\_AS) as part of BioProject PRJEB10018 registered in 2016 by the Sanger Institute. We also retrieved two of the three cgST72142 informed as isolates of human origin, Australia, 2007 (ESC\_GB6748AA\_AS) and 2008 (ESC\_TA3850AA\_AS) as part of BioProjects PRJNA487890 (submitted by University of Minnesota) and PRJNA493523 (submitted by the University of Queensland), respectively. The *in silico* analysis of these three genomes are summarized in Table S4, and show quite conserved traits regarding acquired resistances, the same set of chromosomal mutations (*gyrA* S83L, *gyrA* D87N, *parC* S80I, *parE* L416F), and a constant in the profile of virulence (*chuA*, *fyuA*, *gad*, *iha*, *irp2*, *iucC*, *iutA*, *kpsE*, *kpsMII K1*, *neuC*, *ompT*, *papA\_F43*, *sat*, *senB*, *sitA*, *terC*, *tratT*, *usp*, *vat*, *yfcV*). Besides, PlasmidFinder confirmed the presence of an IncF [F:-A1:B10] plasmid type in the three genomes. The three ST1193 genomes retrieved from Enterobase were also predicted as human pathogen (probability > 92%) when analyzed with PathogenFinder (Table S4).


The genomic similarity of the cgST4085 and cgST72142 assemblies (five from the present study and three from Enterobase) were further investigated through the SNP comparison based on the core genome sequence (82.69% of the reference genome LREC-269) using CSI phylogeny 1.4 (Fig. 1). The phylogenetic dendrogram showed that seven of the eight ST1193 genomes clustered with only 15 to 103 SNP differences. The LREC-270 exhibited the maximum distance, ranging between 140 (in comparison with ESC\_TA3850AA) to 204 SNPs (in comparison with LREC-273).

## DISCUSSION

Despite the public health burden implications and derived costs, uUTIs are not systematically monitored, which also means a lack of data regarding the clonal diversity of the *E. coli* involved. Within scientific references, most studies do not differentiate complicated UTI from uUTI, or even from other extraintestinal infections. Likewise, it is not always possible to discriminate the origin of the isolate (hospital or primary health care centers), giving rise to misinterpretations. To avoid this possible bias, we addressed the characterization, using a clonal diagnosis approach, of nonduplicated *E. coli* isolates causing uUTI in women attending primary health care centers associated to the HUCA hospital under a specific pilot study on uUTI named URIPROAS.

It is important to underline that no set of genes has been found to unequivocally characterize ExPEC and the different categories within a group defined by its isolation from infections outside the intestinal tract. Many cases of bloodstream infections are preceded by an episode of UTI, and therefore UPEC are considered as a subgroup of ExPEC, which also comprise avian pathogenic *E. coli* (APEC) and neonatal meningitis *E. coli* (NMEC) (23). Nevertheless, certain virulence traits have been statistically associated with the pathogenic potential of the isolates, which can be used in a predictive way (24, 25) together with the identification of the so-called global extraintestinal clonal groups of *E. coli* such as ST131 (26). In this study, we used two concepts, namely, the pathogenic categorization and the status of the isolates. Thus, the 100 *E. coli* analyzed here, and clinically recovered from urine as the only pathogen involved in uUTI cases, are UPEC, defined as a subcategory of the ExPEC group. The second concept applied here is the status (UPEC and ExPEC) to differentiate, based on statistical criteria, isolates with higher pathogenic potential. Spurbeck et al. (25) found that *E. coli* isolates carrying *vat*, *fyuA*, *chuA*, and *yfcV* efficiently colonize the urinary tract. Their results indicated that a predictor gene (PG) score of 3 or 4 of those is indicative of status UPEC, and isolates with a PG score of 4 may be highly virulent. In addition, *iutA* and *kpsM II* genes are the most prevalent traits of the status ExPEC scheme (24) for positive isolates, and they are also prevailing in isolates causing extraintestinal infections (18, 27).

The IDSA guidelines recommend trimethoprim-sulfamethoxazole if the local resistance prevalence in *E. coli* is  $\leq 20\%$ , and the use of nitrofurantoin and fosfomicin as next-choice antibiotics for uUTI. For pyelonephritis, empirical fluoroquinolone (FQ) treatment is suggested if local resistance prevalence in *E. coli* is  $\leq 10\%$  (7). In our study,



**FIG 1** Phylogenetic dendrogram based on the SNP counts per substitution within the core genome of the ST1193 isolates (five recovered in our study and three retrieved from Enterobase: ESC\_FA9684AA\_AS, ESC\_TA3850AA\_AS, ESC\_GB6748AA\_AS). The comparison of the WGS data sets resulting in a core genome represented by 82.69% of the reference genome (LREC-269). CSI phylogeny version 1.4 (CGE, <https://cge.cbs.dtu.dk/services/CSIPhylogeny/>; parameters used for phylogenetic analysis: min. depth at SNP positions 10 x; min. relative depth at SNP positions: 10 x; min. distance between SNPs (prune): 10 bp; min. SNP quality: 30; min. read mapping quality: 25, a min. Z-score of 1.96 and by ignoring heterozygous SNPs).

conducted in 2020, the resistance rates observed for fosfomycin (4%) and nitrofurantoin (2%) were similar to those reported for Spain by the ECO-SENS European multicenter study on the antimicrobial resistance of uUTI-associated *E. coli* recovered between 1999 and 2000 (11), and by the ARESC (Antimicrobial Resistance Epidemiological



Survey on Cystitis) in a study conducted between 2003 and 2006 in nine European countries (28). We retrospectively checked resistance rates against the same antibiotics among 241 *E. coli* isolates recovered from women aged 18 to 45 years attending the same primary care centers from August to December of 2020. As a result, we found similar data to those reported for the 100 isolates prospectively studied, which further support the suggestion of fosfomycin and nitrofurantoin as empirical treatment of choice for uUTI by *E. coli* (data not shown). Furthermore, our results corroborate the stable resistance rates ( $\sim <4\%$ ) reported for both antibiotics in specific health areas of Spain such as Galicia, Navarra and Madrid (1999 to 2016) in *E. coli* implicated in UTI (29–31), which further support that these antibiotics should be considered as empirical treatment of choice by the community-acquired uUTI by *E. coli*. In contrast, high percentages of resistance to FQ and trimethoprim-sulfamethoxazole were described for Spain in those same reports (29–31). The variability of non-susceptible isolates to FQ ranged between 10.7% in 2003 to 2006 (28) and 36.6% in 2014 to 2016 (29). For trimethoprim-sulfamethoxazole, resistance ranged between 33.8% of the Spanish isolates within the multicenter European study (2003 to 2006) (28) and 25% of the *E. coli* analyzed in 2016 in Madrid (30). Within our uUTI collection, the resistance rates of trimethoprim-sulfamethoxazole (24%) and FQ (ciprofloxacin: 18%; levofloxacin: 17%; and norfloxacin: 28%) also exceed the limit recommended by the therapeutic guides for the use of these antibiotics as empirical treatments (7). Globally, similar circumstances have been described in different countries for UTIs caused by *E. coli* (uncomplicated or not), where the FQ resistance exceeds even 20%, complicating empirical treatment (18, 32, 33).

Clonotype-level antibiograms can provide a more accurate guidance for empirical treatment than the standard based on species-level antibiograms, as previously showed by Tchesnokova et al. (34, 35) Furthermore, clonal antibiograms could be usable over the time and places due to their stability. But before a clinical implementation, the clonotyping test would benefit from the development of clonal reference databases for the follow up of the dynamics of predominant UTI *E. coli* lineages (32). In the present study, we defined the clonal structure of our collection by means of phylogrouping and clonotyping, followed by MLST for the most prevalent PG-CH combinations. In addition, we performed the screening of specific traits associated with the virulence status of isolates due to the strong correlation found previously between virulence-gene profiles and specific lineages of *E. coli* (18, 27, 36). From the hands-on time and cost point of view, this workflow seems a reasonable approach for the surveillance of emerging clones. As reported in different studies, the phylogenetic group B2 is the predominant within UTI isolates, even though other seven *E. coli* phylogroups *sensu stricto* appear represented to a greater or lesser extent (18, 33, 37, 38). Among the 59 different PG-CH combinations determined in our study, 11 *E. coli* clones comprised 46% of the 100 uUTI isolates. These 11 clones include major pandemic clonal lineages of ExPEC, such as ST73, ST141, ST131, ST69, or ST1193, which are globally responsible for up to 50% of all ExPEC-associated extraintestinal infections worldwide (in particular, UTIs, bloodstream infections, and health care-associated infections) (23, 26, 37, 39).

Our findings can be compared with those resulting from the clonal characterization of 196 consecutively isolated *E. coli* causing UTIs and other extraintestinal infections during 2016 in Spain (100 from Lucus Augusti hospital, HULA, in Lugo) and France (96 from Beaujon hospital in Clichy) (18). Nine out of the 11 uUTI prevalent clones recovered in 2020 in our study were also present within the study collection of Flament-Simon et al. (18): B2-ST73 (CH24-103); B2-ST73 (CH24-30); B2-ST131 (CH40-30); B2-ST141 (CH52-5); B2-ST372 (CH103-9); B2-ST404 (CH14-27); B2-ST1193 (CH14-64); D-ST69 (CH35-27); and F-ST59 (CH32-41). A significant difference found between both studies is the prevalence rate of ST131, which accounted for 12% and 11.5% of the isolates in the Spanish (HULA) and French hospitals, respectively, versus 5% of the present study (health care centers associated to HUCA). In contrast, the MDR rates are quite similar (30% here versus 37.2% for the Spanish and French collection), with individual resistant prevalence  $> 20\%$  in both studies

for penicillins, FQs, and trimethoprim-sulfamethoxazole. None of the 100 uUTI isolates analyzed in our study were carriers of ESBL enzymes versus 6.6% isolates reported by Flament-Simon et al. (18) for both hospitals, mainly associated to the prevalent ST131. Despite the absence of ESBL-producing ST131 within the uUTI collection, the three B2-ST131 (CH40-30) isolates of our study exhibited MDR, and the one B2-ST131 (CH40-1196) was FQR. It is also important to note that the health area analyzed here, regarding the whole community-acquired and health care-associated UTIs, exhibits ESBL-producing *E. coli* rates of around 10% (unpublished data). This fact corroborates that despite the global dispersion of *E. coli* in the community, ESBL-producing isolates are commonly related to patients with risk factors such as previous hospitalization and chronic diseases, which are normally rare in young women (40, 41). To summarize, and taking into consideration the miscellaneous nature of the extraintestinal isolates analyzed in the study of Flament-Simon et al. (18) and the different year of isolation (2016), the similarities found suggest that clonal and antibiotic susceptibility surveillance is essential at both local and global level to evaluate the evolutive impact of the antibiotic use on UTIs as a whole (complicated and uncomplicated).

Over the past 2 decades, the emergence of FQR *E. coli* clones such as B2-ST131 (CH40-30), F-ST648 (CH4-27), or B2-ST1193 (CH14-64) has widely contributed to the spread of MDR and treatment failure (42–44). Particularly B2-ST1193 (CH14-64) has been described since 2012 as a newly emerging ExPEC clone, and an important contributor to the FQR within the *E. coli* population across several countries, i.e., France (45), Germany (46), China (47–50), Korea (51), Vietnam (52) and the United States (16, 53). An impacting finding of a study performed on fecal and urine samples from women without documented UTI (2015 to 2016) was the presence of FQR *E. coli* in 8.8% of healthy women, with most bacteria belonging to the pandemic ST131-*H30R* or ST1193 clonal groups (54). According to the authors, these uropathogenic FQR clonal groups have enhanced ability to persist in the gut and cause bacteriuria in healthy women. To date, most ST1193 have been recovered from human samples generally associated with bloodstream infections, UTIs or meningitis, and with limited overlap with animal sources (52, 55). It is also displayed in Enterobase (<https://enterobase.warwick.ac.uk/>), which includes a total of 1,199 ST1193 genomes (December 19, 2021), almost all referred as human origin and only a few recovered from wildlife (seagull), food, bovine, companion animal, or environment.

In the present study, we found an outstanding occurrence of FQR ST1193 isolates (6%) in uUTI. In contrast, Flament-Simon et al. (18) had found a prevalence of 1% among each of the Spanish and French hospital isolates recovered in 2016.

The genomic analysis of our typically lactose negative ST1193 isolates showed similar key genomic characteristics than global ST1193 (56, 57). Thus, the Spanish uUTI isolates were positive for the K1 capsular type, exhibited mutations in gyrase A (*gyrA* D87N and *gyrA* S83L) and DNA topoisomerase IV genes (*parC* S80I and *parE* L416F). An IncF [F-:A1:B10] plasmid type was also common (with the exception of LREC-270) together with other Col-like and/or plasmid Inc. types. We found almost identical virulence profile of traits commonly prevalent in ST1193 (*chuA*, *fyuA*, *iha*, *irp2*, *iucC*, *iutA*, *kpsE*, *kpsMIII*, *neuC*, *ompT*, *sat*, *senB*, *sitA*, *terC*, *usp*, *vat*, *yfcV*). Among those, *senB* is a plasmid-carried enterotoxin gene associated with enhancing bladder colonization and invasion (58). We confirmed that *senB* was present in all our isolates with plasmid assignment. It has been suggested that this virulence trait presence shown by many high-risk ExPEC clones, together with the high prevalence of a IncF [F-:A1:B10] plasmid in *E. coli* ST1193, might be implicated in the epidemiologic spread of this clone (59). None of our isolates were ESBL-producers; however, it is of concern the increasing presence in other countries of ESBL-producing ST1193 isolates with a wide variety of *bla*<sub>CTX-M<sub>ST</sub> including CTX-M-15, CTX-M-27, or CTX-M-55 (55, 57, 59, 60). These studies suggest a transition in sequence type (ST) and in prevalence of ESBL types, as well as a change in the epidemiology of UPEC isolates that must be followed up. Contrary to previous</sub>

studies, we found CRISPR arrays in three of our isolates (59, 61), which exhibited the same CRISPR-cas system.

To investigate the phylogeny of our isolates in a global context, we used genomic data based on the cgMLST scheme and the hierarchical clustering scheme (HierCC) of Enterobase to retrieve three genomes belonging to the cgSTs 4085 and 72142. HierCC, based on core genome multi-locus typing, allows incremental, static, multilevel cluster assignments of genomes (62, 63). Most of the ST1193 genomes displayed in Enterobase (1,178 of 1,199) are assigned into the same HierCC HC50 (26), which means all genomes in this cluster have links no more than 50 alleles apart. Furthermore, ESC\_FA9684AA\_AS (cgST4085), ESC\_TA3850AA\_AS, and ESC\_GB6748AA\_AS (cgST72142) cluster together in HC20 (571) with no more than 20 alleles of difference. The SNP-based phylogenetic tree comparison confirmed the high core genome similarity between the eight genomes (the three from Enterobase and five of the present study). According to the metadata uploaded in Enterobase, this result would prove the fact of a conserved ST1193 clone circulating in different countries and years. As proposed by Zhou et al. (63), a real-time surveillance would benefit from immediate assignments of each genome assembly to hierarchical population structures such as the HierCC scheme of Enterobase.

In conclusion, the present study provides evidence of the importance of urine culture for the treatment for uUTIs based on susceptibility patterns of the isolates. We suggest here that clonal diagnosis, antimicrobial susceptibility testing (AST) and the screening of predictor genes could help in monitoring the risk of progression to a more severe condition, at the individual level, and globally, in the monitoring of UTIs. We also highlight the urgent need of surveillance to detect changes in the dynamics of emerging UPEC clones associated with the spread of FQR, such as the pandemic ST1193 clonal group, which has the potential to acquire additional resistance genes and colonize healthy individuals. Furthermore, our study represents the first report of ST1193 in uUTI in Spain.

## MATERIALS AND METHODS

**E. coli collection.** We conducted a prospective, multicenter, specific pilot study on uUTI named URIPROAS. This study included 100 nonduplicated *E. coli* isolates recovered from urine samples collected in March ( $n = 45$ ) and June/July ( $n = 55$ ) of 2020 from women between 18 and 45 years (median age 34) attending 15 primary health care centers associated to the Hospital Universitario Central de Asturias (HUCA), northern Spain (Table S1). To avoid bias, the first 100 isolates recovered during those periods of time (45 and 55, respectively) were included in the study. The health area of the HUCA hospital serves a population of approximately 330,000.

Bacterial identification was performed by matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF) (Bruker Daltonik, Bremen, Germany) after conventional culture. A reliable result (at the species level) was only considered if the score obtained was higher than 2. The selected isolates were stored at room temperature in nutrient broth (Difco) with 0.75% nutrient agar (Difco) for further characterization in the Reference Laboratory for *E. coli* (LREC-USC) (Table S1).

**PCR screening of virulence traits.** The 100 UPEC isolates recovered from uUTIs were screened by PCR for specific marker traits associated with the status of virulence. Thus, the purpose of the screening was not an exhaustive characterization, but the subtyping of *E. coli* isolates causing the same type of infection (uUTI), bearing in mind that those traits were statistically associated with higher potential pathogenicity and prevalence in previous studies (24, 25, 27). Specifically, the status of uropathogenic *E. coli* (UPEC) was assigned to those isolates positive for  $\geq 3$  of the following marker genes (*chuA*, *fyuA*, *vat*, and *yfcV*) (25). While for the status of extraintestinal *E. coli* (ExPEC), a duplex PCR based on *iutA* (441 bp) and *kpsMIII* (272 bp) genes was performed as described elsewhere (27).

**Phylogroup, clonotype, and sequence type assignment.** The clonal structure of the *E. coli* collection was established by means of phylogrouping, clonotyping and MLST (64–67). Briefly, the phylogroup of the 100 isolates was established according to the PCR-based method developed by Clermont et al. (64, 65), relying on the combination of the presence of four DNA markers followed by allele-specific amplifications, which allows the rapid identification of the eight *E. coli* phylogroups belonging to *E. coli sensu stricto* (A, B1, B2, C, D, E, F, G). The clonotyping was performed by sequencing the internal 469-nucleotide (nt) and 489-nt sequence of the *fumC* (allele obtained from MLST) and *fimH* genes, respectively (66). The MLST was conducted for those isolates belonging to the most prevalent phylogroup-CH combinations ( $\geq 3$  isolates), following the Achtman scheme of seven genes (67). The ST was assigned through the Enterobase website (<http://mlst.warwick.ac.uk/mlst/dbs/Ecoli>).

**Antimicrobial susceptibility testing.** MICs of the 100 *E. coli* isolates were determined using the MicroScan WalkAway System (Beckman Coulter, Brea, CA, USA). A total of 28 drugs were included in the analysis: penicillins (ampicillin/amoxicillin, piperacillin, ticarcillin); antipseudomonal penicillins + beta-lactamase inhibitors

(piperacillin-tazobactam); penicillins + beta-lactamase inhibitors (amoxicillin-clavulanic acid); non-broad spectrum cephalosporins (cefuroxime); broad-spectrum cephalosporins (cefixime, cefotaxime, ceftazidime, cefepime); broad-spectrum cephalosporins + beta-lactamase inhibitors (ceftolozane-tazobactam, ceftazidime-avibactam); carbapenems (imipenem, ertapenem, meropenem); monobactams (aztreonam); fluoroquinolones (norfloxacin, ciprofloxacin, levofloxacin); aminoglycosides (gentamicin, tobramycin, amikacin); glycolcyclines (tigecycline); nitrofurans (nitrofurantoin); phosphonic acids (fosfomicin); folate pathway inhibitors (trimethoprim, trimethoprim-sulfamethoxazole); and polymyxins (colistin). Additionally, colistin susceptibility was analyzed with the standard broth microdilution (BMD) method as described elsewhere (68). Susceptibility testing was interpreted according to EUCAST 2021 breakpoints. Isolates were classified as MDR if displayed resistance to a drug of  $\geq$  three or more of the above-mentioned antimicrobial categories.

**Whole genome sequencing.** Isolates belonging to ST1193 were further investigated by WGS. The genomic DNA libraries for sequencing were prepared using the Nextera XT Library Prep kit (Illumina, CA, USA) according to the manufacturer's recommendation. Libraries were purified using the Mag-Bind RXNPure Plus magnetic beads (Omega Biotek), following the instructions provided by the manufacturer. Then, libraries were pooled in equimolar amounts according to the quantification data provided by the Qubit dsDNA HS Assay (Thermo Fisher Scientific). Lastly, the libraries were sequenced in an Illumina NovaSeq PE150 platform, obtaining 100 to 150 bp paired-end reads which were trimmed (Trim Galore 0.6.0) and filtered according to quality criteria (FastQC 0.11.9). The quality-filtered reads were assembled *de novo* using Unicycler (v0.4.8) (69), which uses an adapted SPAdes (v3.14.0) assembling algorithm (70). For the comprehensive typing of the isolates, the assembled contigs were analyzed using different bioinformatics tools of the Center for Genomic Epidemiology (CGE) as specified, and applying the thresholds suggested by default when required (minimum identity of 95% and coverage of 60%): SeroTypeFinder 2.0 (71), CHTyper 1.0 (72), MobileElementFinder 1.03 (73), PlasmidFinder 2.1 and pMLST 2.0 (74). For the phylogenetic typing, two different MLST schemes were applied: *E. coli* #1 (67) and *E. coli* #2 (22). Additionally, cgMLSTFinder1.1 (75) was applied for the core genome multi-locus typing (cgMLST) from the raw reads of the isolates. cgMLSTFinder software runs KMA (k-mer alignment) against the Enterobase (core genome MLST, cgMLST) database, based on a total number of 2,513 conserved loci analyzed (62). In addition to this typing, lineage-specific gene markers based on the sequence of CRISPRCasFinder software (<https://crisprcas.i2bc.paris-saclay.fr/>) was used to identify and type CRISPR and Cas systems within the genomes.

Two different tools were used for the identification of acquired genes and/or chromosomal mutations mediating antimicrobial resistance, ResFinder 4.1 (76–78) first, and then ABRicate v1.0.1 (<https://github.com/tseemann/abricate>) was run against the curated CARD database (<https://card.mcmaster.ca/home>). The identification of acquired virulence genes was performed using the web-based tool VirulenceFinder 2.0 (79, 80), and then ABRicate v1.0.1 was run against the virulence factor database (VFDB) (81) where results were filtered only for *E. coli* entries. Besides, the bacteria's pathogenicity toward human hosts was predicted using PathogenFinder 1.1 (82).

A phylogeny based on the concatenated alignment of the high-quality SNPs was inferred using CSI phylogeny 1.4 (Call SNPs & Infer Phylogeny) as described (83). Enterobase (<https://enterobase.warwick.ac.uk/>) was searched for genomes belonging to ST1193 (according to the Achtman 7-gene MLST scheme) and specific core genome MLST (cgMLST) sequences, whose assemblies were retrieved for comparative purposes.

**Statistical analysis.** Comparisons of proportions were tested using a two-tailed Fisher's exact test. *P* values < 0.05 were considered statistically significant.

**Data availability.** The nucleotide sequence of the ST1193 LREC isolates were deposited in the European Nucleotide Archive (ENA) with the following accession (ERR7926813 to ERR7926817) and BioSample (SAMEA11224177 to SAMEA11224181) codes, as part of BioProject ID PRJEB49681.

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1**, XLSX file, 0.03 MB.

**SUPPLEMENTAL FILE 2**, XLSX file, 0.03 MB.

**SUPPLEMENTAL FILE 3**, XLSX file, 0.04 MB.

**SUPPLEMENTAL FILE 4**, XLSX file, 0.01 MB.

## ACKNOWLEDGMENTS

This study was supported by the projects and funds PID2019-104439RB-C21/AEI/10.13039/501100011033 from the Agencia Estatal de Investigación (AEI, Spain), co-funded by the European Regional Development Fund of the European Union: A Way to Make Europe (ERDF); FIS P117-00728 (Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain), co-funded by ERDF; GRUPIN IDI/2022/000033 by the Regional Ministry of Science of Asturias (IDI/2022/000033). ED431C 2021/11 from the Consellería de Cultura, Educación e Ordenación Universitaria (Xunta de Galicia) and ERDF. I.G.-M. and V.G. acknowledge the Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia for their post-doctoral grants (Grant Number ED481B-2021-006 and ED481-B2018/018, respectively).

The research stay of I.G-M at the Hospital Universitario Central de Asturias was funded by a grant from the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). L.L. acknowledges the Ministry of Education of Spain for her predoctoral grant FPU19/01127.

The present study was approved by the ethics committee of the Principality of Asturias within the framework of the study URIPROAS.

## REFERENCES

1. Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. 2017. The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998–2011. *Open Forum Infect Dis* 4: ofw281. <https://doi.org/10.1093/ofid/ofw281>.
2. François M, Hanslik T, Dervaux B, Le Strat Y, Souty C, Vaux S, Maugat S, Rondet C, Sarazin M, Heym B, Coignard B, Rossignol L. 2016. The economic burden of urinary tract infections in women visiting general practices in France: a cross-sectional survey. *BMC Health Serv Res* 16:365. <https://doi.org/10.1186/s12913-016-1620-2>.
3. Bates J, Thomas-Jones E, Pickles T, Kirby N, Gal M, Bongard E, Hood K, Francis N, Little P, Moore M, Rumsby K, Llor C, Burgman C, Verheij T, Cohen D, Wootton M, Howe R, Butler CC. 2014. Point of care testing for urinary tract infection in primary care (POETIC): protocol for a randomised controlled trial of the clinical and cost effectiveness of FLEXICULT™ informed management of uncomplicated UTI in primary care. *BMC Fam Pract* 15:187. <https://doi.org/10.1186/s12875-014-0187-4>.
4. Car J. 2006. Urinary tract infections in women: diagnosis and management in primary care. *BMJ* 332:94–97. <https://doi.org/10.1136/bmj.332.7533.94>.
5. Ong DS, Kuyvenhoven MM, van Dijk L, Verheij TJ. 2008. Antibiotics for respiratory, ear and urinary tract disorders and consistency among GPs. *J Antimicrob Chemother* 62:587–592. <https://doi.org/10.1093/jac/dkn230>.
6. Salvatore S, Salvatore S, Cattoni E, Siesto G, Serati M, Sorice P, Torella M. 2011. Urinary tract infections in women. *Eur J Obstet Gynecol Reprod Biol* 156:131–136. <https://doi.org/10.1016/j.ejogrb.2011.01.028>.
7. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, American IDSo, Diseases ESfMal. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* 52:e103–20–e120. <https://doi.org/10.1093/cid/ciq257>.
8. Llor C, Hernández S. 2010. Infectious disease in primary care: 1-year prospective study. *Enferm Infecc Microbiol Clin* 28:222–226. <https://doi.org/10.1016/j.eimc.2009.03.014>.
9. Foxman B. 2014. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am* 28:1–13. <https://doi.org/10.1016/j.idc.2013.09.003>.
10. de Cueto M, Aliaga L, Alós JI, Canut A, Los-Arcos I, Martínez JA, Mensa J, Pintado V, Rodríguez-Pardo D, Yuste JR, Pigrau C. 2017. Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). *Enferm Infecc Microbiol Clin* 35:314–320. <https://doi.org/10.1016/j.eimc.2016.11.005>.
11. Kahlmeter G, Sens ECO. 2003. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. *J Antimicrob Chemother* 51:69–76. <https://doi.org/10.1093/jac/dkg028>.
12. Kornfält Isberg H, Hedin K, Melander E, Mölsted S, Beckman A. 2021. Uncomplicated urinary tract infection in primary health care: presentation and clinical outcome. *Infect Dis (Lond)* 53:94–101. <https://doi.org/10.1080/23744235.2020.1834138>.
13. Pitout JD, Chan WW, Church DL. 2016. Tackling antimicrobial resistance in lower urinary tract infections: treatment options. *Expert Rev Anti Infect Ther* 14:621–632. <https://doi.org/10.1080/14787210.2016.1188004>.
14. Saperston KN, Shapiro DJ, Hersh AL, Copp HL. 2014. A comparison of inpatient versus outpatient resistance patterns of pediatric urinary tract infection. *J Urol* 191:1608–1613. <https://doi.org/10.1016/j.juro.2013.10.064>.
15. Nicolas-Chanoine MH, Bertrand X, Madec JY. 2014. *Escherichia coli* ST131, an intriguing clonal group. *Clin Microbiol Rev* 27:543–574. <https://doi.org/10.1128/CMR.00125-13>.
16. Tchesnokova VL, Rechkina E, Larson L, Ferrier K, Weaver JL, Schroeder DW, She R, Butler-Wu SM, Aguero-Rosenfeld ME, Zerr D, Fang FC, Ralston J, Riddell K, Scholes D, Weissman S, Parker K, Spellberg B, Johnson JR, Sokurenko EV. 2019. Rapid and extensive expansion in the United States of a new multidrug-resistant *Escherichia coli* clonal group, sequence type 1193. *Clin Infect Dis* 68:334–337. <https://doi.org/10.1093/cid/ciy525>.
17. Mamani R, Flament-Simon SC, García V, Mora A, Alonso MP, López C, García-Meniño I, Díaz-Jiménez D, Blanco JE, Blanco M, Blanco J. 2019. Sequence types, clonotypes, serotypes, and virotypes of extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* causing Bacteraemia in a Spanish hospital over a 12-year period (2000–2011). *Front Microbiol* 10:1530. <https://doi.org/10.3389/fmicb.2019.01530>.
18. Flament-Simon SC, Nicolas-Chanoine MH, García V, Duprilot M, Mayer N, Alonso MP, García-Meniño I, Blanco JE, Blanco M, Blanco J. 2020. Clonal structure, virulence factor-encoding genes and antibiotic resistance of *Escherichia coli*, causing urinary tract infections and other extraintestinal infections in humans in Spain and France during 2016. *Antibiotics (Basel)* 9:161. <https://doi.org/10.3390/antibiotics9040161>.
19. Kim B, Kim JH, Lee Y. 2022. Virulence factors associated with *Escherichia coli* bacteremia and urinary tract infection. *Ann Lab Med* 42:203–212. <https://doi.org/10.3343/alm.2022.42.2.203>.
20. Nicolle L, Anderson PA, Conly J, Mainprize TC, Meuser J, Nickel JC, Senikas VM, Zhanel GG. 2006. Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. *Can Fam Physician* 52:612–618.
21. Butler CC, Francis N, Thomas-Jones E, Llor C, Bongard E, Moore M, Little P, Bates J, Lau M, Pickles T, Gal M, Wootton M, Kirby N, Gillespie D, Rumsby K, Brugman C, Hood K, Verheij T. 2017. Variations in presentation, management, and patient outcomes of urinary tract infection: a prospective four-country primary care observational cohort study. *Br J Gen Pract* 67:e830–e841. <https://doi.org/10.3399/bjgp17X693641>.
22. Jaureguy F, Landraud L, Passet V, Diancourt L, Frapy E, Guigon G, Carbonnelle E, Lortholary O, Clermont O, Denamur E, Picard B, Nassif X, Brisse S. 2008. Phylogenetic and genomic diversity of human bacteremic *Escherichia coli* strains. *BMC Genomics* 9:560. <https://doi.org/10.1186/1471-2164-9-560>.
23. Riley LW. 2014. Pandemic lineages of extraintestinal pathogenic *Escherichia coli*. *Clin Microbiol Infect* 20:380–390. <https://doi.org/10.1111/1469-0691.12646>.
24. Johnson JR, Murray AC, Gajewski A, Sullivan M, Snippes P, Kuskowski MA, Smith KE. 2003. Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic *Escherichia coli* from retail chicken products. *Antimicrob Agents Chemother* 47:2161–2168. <https://doi.org/10.1128/AAC.47.7.2161-2168.2003>.
25. Spurbeck RR, Dinh PC, Jr, Walk ST, Stapleton AE, Hooton TM, Nolan LK, Kim KS, Johnson JR, Mobley HL. 2012. *Escherichia coli* isolates that carry *vat*, *fyuA*, *chuA*, and *yfcV* efficiently colonize the urinary tract. *Infect Immun* 80:4115–4122. <https://doi.org/10.1128/IAI.00752-12>.
26. Manges AR, Geum HM, Guo A, Edens TJ, Fibke CD, Pitout JDD. 2019. Global extraintestinal pathogenic *Escherichia coli* (ExPEC) lineages. *Clin Microbiol Rev* 32. <https://doi.org/10.1128/CMR.00135-18>.
27. Díaz-Jiménez D, García-Meniño I, Herrera A, Lestón L, Mora A. 2021. Microbiological risk assessment of Turkey and chicken meat for consumer: Significant differences regarding multidrug resistance, *mcr* or presence of hybrid aEPEC/ExPEC pathotypes of *E. coli*. *Food Control* 123: 107713. <https://doi.org/10.1016/j.foodcont.2020.107713>.
28. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. 2009. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. *Int J Antimicrob Agents* 34:407–413. <https://doi.org/10.1016/j.ijantimicag.2009.04.012>.

29. Aguinaga A, Gil-Setas A, Mazón RA, Alvaro A, García-Irure JJ, Navascués A, Ezpeleta BC. 2018. Uncomplicated urinary tract infections. *An Sist Sanit Navar* 41:17–26.
30. Grados MC, Thuissard JJ, Alós JI. 2019. Stratification by demographic and clinical data of the antibiotic susceptibility of *Escherichia coli* from urinary tract infections of the community. *Aten Primaria* 51:494–498. <https://doi.org/10.1016/j.aprim.2018.06.004>.
31. Treviño M, Losada I, Fernández-Pérez B, Coira A, Peña-Rodríguez MF, Hervada X, Sgs G. 2016. Surveillance of antimicrobial susceptibility of *Escherichia coli* producing urinary tract infections in Galicia (Spain). *Rev Esp Quimioter* 29:86–90.
32. Tchesnokova V, Avagyan H, Rechkina E, Chan D, Muradova M, Haile HG, Radey M, Weissman S, Riddell K, Scholes D, Johnson JR, Sokurenko EV. 2017. Bacterial clonal diagnostics as a tool for evidence-based empiric antibiotic selection. *PLoS One* 12:e0174132. <https://doi.org/10.1371/journal.pone.0174132>.
33. Zeng Q, Xiao S, Gu F, He W, Xie Q, Yu F, Han L. 2021. Antimicrobial resistance and molecular epidemiology of uropathogenic *Escherichia coli* isolated from female patients in Shanghai, China. *Front Cell Infect Microbiol* 11:653983. <https://doi.org/10.3389/fcimb.2021.653983>.
34. Tchesnokova V, Billig M, Chattopadhyay S, Linardopoulou E, Aprikian P, Roberts PL, Skrivankova V, Johnston B, Gileva A, Igusheva I, Toland A, Riddell K, Rogers P, Qin X, Butler-Wu S, Cookson BT, Fang FC, Kahl B, Price LB, Weissman SJ, Limaye A, Scholes D, Johnson JR, Sokurenko EV. 2013. Predictive diagnostics for *Escherichia coli* infections based on the clonal association of antimicrobial resistance and clinical outcome. *J Clin Microbiol* 51:2991–2999. <https://doi.org/10.1128/JCM.00984-13>.
35. Tchesnokova V, Avagyan H, Billig M, Chattopadhyay S, Aprikian P, Chan D, Pseunova J, Rechkina E, Riddell K, Scholes D, Fang FC, Johnson JR, Sokurenko EV. 2016. A novel 7-single nucleotide polymorphism-based clonotyping test allows rapid prediction of antimicrobial susceptibility of extraintestinal *Escherichia coli* directly from urine specimens. *Open Forum Infect Dis* 3:ofw002. <https://doi.org/10.1093/ofid/ofw002>.
36. Flament-Simon S-C, García V, Dupilot M, Mayer N, Alonso MP, García-Meniño I, Blanco JE, Blanco M, Nicolas-Chanoine M-H, Blanco J. 2020. High prevalence of ST131 subclades C2-H30Rx and C1-M27 among extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* causing human extraintestinal infections in patients from two hospitals of Spain and France during 2015. *Front Cell Infect Microbiol* 10:125. <https://doi.org/10.3389/fcimb.2020.00125>.
37. Toval F, Köhler CD, Vogel U, Wagenlehner F, Mellmann A, Fruth A, Schmidt MA, Karch H, Bielaszewska M, Dobrindt U. 2014. Characterization of *Escherichia coli* isolates from hospital inpatients or outpatients with urinary tract infection. *J Clin Microbiol* 52:407–418. <https://doi.org/10.1128/JCM.02069-13>.
38. Lin WH, Zhang YZ, Liu PY, Chen PS, Wang S, Kuo PY, Thuy TTD, Duong TTT, Wen LL, Hsieh YH, Wang MC, Kao CY. 2021. Distinct characteristics of *Escherichia coli* isolated from patients with urinary tract infections in a medical center at a ten-year interval. *Pathogens* 10:1156. <https://doi.org/10.3390/pathogens10091156>.
39. Kallonen T, Brodrick HJ, Harris SR, Corander J, Brown NM, Martin V, Peacock SJ, Parkhill J. 2017. Systematic longitudinal survey of invasive *Escherichia coli* in England demonstrates a stable population structure only transiently disturbed by the emergence of ST131. *Genome Res* 27:1437–1449. <https://doi.org/10.1101/gr.216606.116>.
40. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, Lewis JS, Howard WJ, Johnson LE, Polsky B, Jorgensen JH, Richter SS, Shutt KA, Paterson DL. 2013. Community-associated extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* infection in the United States. *Clin Infect Dis* 56:641–648. <https://doi.org/10.1093/cid/cis942>.
41. Frödén I, Hasan B, Sylvén I, Coorens M, Naclér P, Giske CG. 2020. Extended-spectrum- $\beta$ -lactamase- and plasmid AmpC-producing *Escherichia coli* causing community-onset bloodstream infection: association of bacterial clones and virulence genes with septic shock, source of infection, and recurrence. *Antimicrob Agents Chemother* 64. <https://doi.org/10.1128/AAC.02351-19>.
42. Schaufler K, Semmler T, Wieler LH, Trott DJ, Pitout J, Peirano G, Bonnedahl J, Dolejska M, Literak I, Fuchs S, Ahmed N, Grobbel M, Torres C, McNally A, Pickard D, Ewers C, Croucher NJ, Corander J, Guenther S. 2019. Genomic and functional analysis of emerging virulent and multidrug-resistant lineage *Escherichia coli* sequence type 648. *Antimicrob Agents Chemother* 63. <https://doi.org/10.1128/AAC.00243-19>.
43. Johnson JR, Johnston BD, Porter SB, Clabots C, Bender TL, Thuras P, Trott DJ, Cobbold R, Mollinger J, Ferrieri P, Drawz S, Banerjee R. 2019. Rapid emergence, subsidence, and molecular detection of *Escherichia coli* sequence type 1193-*fimH64*, a new disseminated multidrug-resistant commensal and extraintestinal pathogen. *J Clin Microbiol* 57. <https://doi.org/10.1128/JCM.01664-18>.
44. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR, Allen BL, Baracco GJ, Bedimo R, Bessesen M, Bonomo RA, Brecher SM, Brown ST, Castellino L, Desai AS, Fernau F, Fisher MA, Fleckenstein J, Fleming CS, Fries NJ, Kan VL, Kauffman CA, Klutts S, Ohl M, Russo T, Swiatlo A, Swiatlo E, on behalf of the VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. 2013. *Escherichia coli* sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. *Clin Infect Dis* 57:1256–1265. <https://doi.org/10.1093/cid/cit503>.
45. Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S, Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children. 2020. Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017. *J Antimicrob Chemother* 75:96–105. <https://doi.org/10.1093/jac/dkz423>.
46. Valenza G, Werner M, Eisenberger D, Nickel S, Lehner-Reindl V, Höller C, Bogdan C. 2019. First report of the new emerging global clone ST1193 among clinical isolates of extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Escherichia coli* from Germany. *J Glob Antimicrob Resist* 17:305–308. <https://doi.org/10.1016/j.jgar.2019.01.014>.
47. Wu J, Lan F, Lu Y, He Q, Li B. 2017. Molecular characteristics of ST1193 clone among phylogenetic group B2 Non-ST131 fluoroquinolone-resistant *Escherichia coli*. *Front Microbiol* 8:2294. <https://doi.org/10.3389/fmicb.2017.02294>.
48. Xia L, Liu Y, Xia S, Kudinha T, Xiao SN, Zhong NS, Ren GS, Zhuo C. 2017. Prevalence of ST1193 clone and Inc11/ST16 plasmid in *E. coli* isolates carrying blaCTX-M-55 gene from urinary tract infections patients in China. *Sci Rep* 7:44866. <https://doi.org/10.1038/srep44866>.
49. Chen X, Zou Q, Zhang W, Wang R, Yu F, Chen Y. 2019. Clinical features and microbiological characteristics of hospital- and community-onset *Escherichia coli* bloodstream infection. *J Med Microbiol* 68:178–187. <https://doi.org/10.1099/jmm.0.000904>.
50. Ding Y, Zhang J, Yao K, Gao W, Wang Y. 2021. Molecular characteristics of the new emerging global clone ST1193 among clinical isolates of *Escherichia coli* from neonatal invasive infections in China. *Eur J Clin Microbiol Infect Dis* 40:833–840. <https://doi.org/10.1007/s10096-020-04079-0>.
51. Kim Y, Oh T, Nam YS, Cho SY, Lee HJ. 2017. Prevalence of ST131 and ST1193 Among Bloodstream Isolates of *Escherichia coli* not Susceptible to Ciprofloxacin in a Tertiary Care University Hospital in Korea, 2013 – 2014. *Clin Lab* 63:1541–1543. <https://doi.org/10.7754/Clin.Lab.2017.170319>.
52. Nguyen MN, Hoang HTT, Xavier BB, Lammens C, Le HT, Hoang NTB, Nguyen ST, Pham NT, Goossens H, Dang AD, Malhotra-Kumar S. 2021. Prospective One Health genetic surveillance in Vietnam identifies distinct bla<sub>CTX-M</sub>-harbouring *Escherichia coli* in food-chain and human-derived samples. *Clin Microbiol Infect* 27:1515.e1–1515.e8. <https://doi.org/10.1016/j.cmi.2021.01.006>.
53. Cole BK, Ilikj M, McCloskey CB, Chavez-Bueno S. 2019. Antibiotic resistance and molecular characterization of bacteremia *Escherichia coli* isolates from newborns in the United States. *PLoS One* 14:e0219352. <https://doi.org/10.1371/journal.pone.0219352>.
54. Tchesnokova VL, Rechkina E, Chan D, Haile HG, Larson L, Ferrier K, Schroeder DW, Solyanik T, Shibuya S, Hansen K, Ralston JD, Riddell K, Scholes D, Sokurenko EV. 2020. Pandemic Uropathogenic Fluoroquinolone-resistant *Escherichia coli* Have Enhanced Ability to Persist in the Gut and Cause Bacteriuria in Healthy Women. *Clin Infect Dis* 70:937–939. <https://doi.org/10.1093/cid/ciz547>.
55. Nguyen Q, Nguyen TTN, Pham P, Chau V, Nguyen LPH, Nguyen TD, Ha TT, Le NTQ, Vu DT, Baker S, Thwaites GE, Rabaa MA, Pham DT. 2021. Genomic insights into the circulation of pandemic fluoroquinolone-resistant extra-intestinal pathogenic *Escherichia coli* ST1193 in Vietnam. *Microb Genom* 7.
56. Johnson TJ, Elnekave E, Miller EA, Munoz-Aguayo J, Flores FC, Johnston B, Nielson DW, Logue CM, Johnson JR. 2019. Phylogenomic Analysis of Extraintestinal Pathogenic *Escherichia coli* Sequence Type 1193, an Emerging Multidrug-Resistant Clonal Group. *Antimicrob Agents Chemother* 63. <https://doi.org/10.1128/AAC.01913-18>.
57. Peirano G, Matsumara Y, Nobrega D, DeVinny R, Pitout J. 2021. Population-based epidemiology of *Escherichia coli* ST1193 causing blood stream infections in a centralized Canadian region. *Eur J Clin Microbiol Infect Dis* <https://doi.org/10.1007/s10096-021-04373-5>.

58. Cusumano CK, Hung CS, Chen SL, Hultgren SJ. 2010. Virulence plasmid harbored by uropathogenic *Escherichia coli* functions in acute stages of pathogenesis. *Infect Immun* 78:1457–1467. <https://doi.org/10.1128/IAI.01260-09>.
59. Huang J, Zhao Z, Zhang Q, Zhang S, Chen M, Qiu H, Cao Y, Li B. 2021. Phylogenetic analysis reveals distinct evolutionary trajectories of the fluoroquinolones-resistant *Escherichia coli* ST1193 from Fuzhou. *China Front Microbiol* 12:746995. <https://doi.org/10.3389/fmicb.2021.746995>.
60. Zeng Q, Xiao S, Gu F, He W, Xie Q, Yu F, Han L. 2021. Antimicrobial resistance and molecular epidemiology of uropathogenic *Escherichia coli* isolated from female patients in Shanghai, China. *Front Cell Infect Microbiol* 11:653983.
61. Al-Farsi HM, Camporeale A, Ininbergs K, Al-Azri S, Al-Muharrmi Z, Al-Jardani A, Giske CG. 2020. Clinical and molecular characteristics of carbapenem non-susceptible *Escherichia coli*: a nationwide survey from Oman. *PLoS One* 15:e0239924. <https://doi.org/10.1371/journal.pone.0239924>.
62. Zhou Z, Alikhan NF, Mohamed K, Fan Y, Achtman M, Group AS, Agama Study Group. 2020. The Enterobase user's guide, with case studies on *Salmonella* transmissions, *Yersinia pestis* phylogeny, and *Escherichia coli* core genomic diversity. *Genome Res* 30:138–152. <https://doi.org/10.1101/gr.251678.119>.
63. Zhou Z, Charlesworth J, Achtman M. 2021. HierCC: a multi-level clustering scheme for population assignments based on core genome MLST. *Bioinformatics* 37:3645–3646. <https://doi.org/10.1093/bioinformatics/btab234>.
64. Clermont O, Christenson JK, Denamur E, Gordon DM. 2013. The Clermont *Escherichia coli* phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. *Environ Microbiol Rep* 5:58–65. <https://doi.org/10.1111/1758-2229.12019>.
65. Clermont O, Dixit OVA, Vangchhia B, Condamine B, Dion S, Bridier-Nahmias A, Denamur E, Gordon D. 2019. Characterization and rapid identification of phylogroup G in *Escherichia coli*, a lineage with high virulence and antibiotic resistance potential. *Environ Microbiol* 21:3107–3117. <https://doi.org/10.1111/1462-2920.14713>.
66. Weissman SJ, Johnson JR, Tchesnokova V, Billig M, Dykhuizen D, Riddell K, Rogers P, Qin X, Butler-Wu S, Cookson BT, Fang FC, Scholes D, Chattopadhyay S, Sokurenko E. 2012. High-resolution two-locus clonal typing of extraintestinal pathogenic *Escherichia coli*. *Appl Environ Microbiol* 78:1353–1360. <https://doi.org/10.1128/AEM.06663-11>.
67. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR, Maiden MC, Ochman H, Achtman M. 2006. Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol Microbiol* 60:1136–1151. <https://doi.org/10.1111/j.1365-2958.2006.05172.x>.
68. García-Meniño I, Lumbreras P, Valledor P, Díaz-Jiménez D, Lestón L, Fernández J, Mora A. 2020. Comprehensive statistical evaluation of Etest, UMIC, MicroScan and disc diffusion versus standard broth microdilution: workflow for an accurate detection of Colistin-Resistant and Mcr-positive *E. coli*. *Antibiotics (Basel)* 9.
69. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput Biol* 13:e1005595. <https://doi.org/10.1371/journal.pcbi.1005595>.
70. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Pribelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 19:455–477. <https://doi.org/10.1089/cmb.2012.0021>.
71. Joensen KG, Tetzschner AM, Iguchi A, Aarestrup FM, Scheutz F. 2015. Rapid and easy in silico serotyping of *Escherichia coli* isolates by use of whole-genome sequencing data. *J Clin Microbiol* 53:2410–2426. <https://doi.org/10.1128/JCM.00008-15>.
72. Roer L, Johannesen TB, Hansen F, Stegger M, Tchesnokova V, Sokurenko E, Garibay N, Allesøe R, Thomsen MCF, Lund O, Hasman H, Hammerum AM. 2018. CHType, a web tool for subtyping of extraintestinal pathogenic *Escherichia coli* based on the *fumC* and *fimH* alleles. *J Clin Microbiol* 56. <https://doi.org/10.1128/JCM.00063-18>.
73. Johansson MHK, Bortolaia V, Tansirichaiya S, Aarestrup FM, Roberts AP, Petersen TN. 2021. Detection of mobile genetic elements associated with antibiotic resistance in *Salmonella enterica* using a newly developed web tool: MobileElementFinder. *J Antimicrob Chemother* 76:101–109. <https://doi.org/10.1093/jac/dkaa390>.
74. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903. <https://doi.org/10.1128/AAC.02412-14>.
75. Clausen PTL, Aarestrup FM, Lund O. 2018. Rapid and precise alignment of raw reads against redundant databases with KMA. *BMC Bioinformatics* 19:307. <https://doi.org/10.1186/s12859-018-2336-6>.
76. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesøe RL, Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK, Stingl K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum MF, Duggett NA, Kempf I, Nykäsenoja S, Olkkola S, Wiczorek K, Amaro A, Clemente L, Mossong J, Losch S, Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for predictions of phenotypes from genotypes. *J Antimicrob Chemother* 75:3491–3500. <https://doi.org/10.1093/jac/dkaa345>.
77. Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. 2017. PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens. *J Antimicrob Chemother* 72:2764–2768. <https://doi.org/10.1093/jac/dkx217>.
78. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: architecture and applications. *BMC Bioinformatics* 10:421. <https://doi.org/10.1186/1471-2105-10-421>.
79. Malberg Tetzschner AM, Johnson JR, Johnston BD, Lund O, Scheutz F. 2020. Genotyping of *Escherichia coli* isolates for extraintestinal virulence genes by use of whole-genome sequencing data. *J Clin Microbiol* 58. <https://doi.org/10.1128/JCM.01269-20>.
80. Joensen KG, Scheutz F, Lund O, Hasman H, Kaas RS, Nielsen EM, Aarestrup FM. 2014. Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic *Escherichia coli*. *J Clin Microbiol* 52:1501–1510. <https://doi.org/10.1128/JCM.03617-13>.
81. Liu B, Zheng D, Jin Q, Chen L, Yang J. 2019. VFDB 2019: a comparative pathogenomic platform with an interactive web interface. *Nucleic Acids Res* 47:D687–D692. <https://doi.org/10.1093/nar/gky1080>.
82. Cosentino S, Voldby Larsen M, Møller Aarestrup F, Lund O. 2013. PathogenFinder-distinguishing friend from foe using bacterial whole genome sequence data. *PLoS One* 8:e77302. <https://doi.org/10.1371/journal.pone.0077302>.
83. Kaas RS, Leekitcharoenphon P, Aarestrup FM, Lund O. 2014. Solving the problem of comparing whole bacterial genomes across different sequencing platforms. *PLoS One* 9:e104984. <https://doi.org/10.1371/journal.pone.0104984>.